MNKD
MannKind Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.06
+2.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 393.6M | 349.0M | 285.5M | 199.0M | 99.8M |
| Cost of Revenue | 95.7M | 61.2M | 76.6M | 62.8M | 57.5M |
| Gross Profit | 297.9M | 287.8M | 208.9M | 136.2M | 42.3M |
| Operating Expenses | |||||
| R&D Expense | 76.9M | 66.3M | 45.9M | 31.3M | 19.7M |
| SG&A Expense | 199.9M | 144.1M | 94.3M | 94.3M | 91.5M |
| General & Admin Expense | 72.7M | — | — | 42.5M | 37.7M |
| Selling & Marketing Expense | 14.7M | — | — | 51.8M | 53.8M |
| Other Expenses | 13.4M | 38.5M | (3.9M) | 1.9M | (4.8M) |
| Total Operating Expenses | 290.2M | 249.0M | 136.3M | 127.5M | 106.4M |
| Cost and Expenses | 385.9M | 310.2M | 212.9M | 190.3M | 163.9M |
| Operating Income (EBIT) | 7.8M | 38.8M | 72.6M | 8.7M | (64.1M) |
| Non-Operating | |||||
| Interest Income | 7.8M | — | 12.6M | 6.2M | 2.5M |
| Interest Expense | 44.8M | 13.8M | 38.0M | 25.2M | 24.8M |
| Net Interest Income | (37.0M) | (13.8M) | (25.4M) | (19.0M) | (22.3M) |
| Other Non-Op Income/Expense | (56.4M) | (37.4M) | (42.1M) | (19.1M) | (23.3M) |
| Non-Operating Income (excl Interest) | (2.2M) | 23.6M | 4.1M | (1.9M) | (1.5M) |
| EBT (Pre-Tax Income) | (48.7M) | 1.4M | 30.5M | (10.4M) | (87.4M) |
| Income Tax Expense | (5.0M) | (4.5M) | 2.9M | 1.6M | — |
| Bottom Line | |||||
| Net Income | (43.6M) | 5.9M | 27.6M | (11.9M) | (87.4M) |
| Earnings from Cont. Ops | (43.6M) | 5.9M | 27.6M | (11.9M) | (87.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (43.6M) | 5.9M | 27.6M | (11.9M) | (87.4M) |
| Per Share | |||||
| Basic EPS | ($0.14) | $0.02 | $0.10 | ($0.04) | ($0.44) |
| Diluted EPS | ($0.14) | $0.02 | $0.10 | ($0.04) | ($0.44) |
| Revenue Per Share | $1.27 | $1.14 | $1.04 | $0.75 | $0.39 |
| Shares | |||||
| Basic Shares Outstanding | 309.2M | 305.6M | 274.4M | 267.0M | 257.1M |
| Diluted Shares Outstanding | 309.2M | 314.1M | 283.8M | 267.0M | 257.1M |
| Profitability Metrics | |||||
| EBITDA | 30.7M | 27.5M | 77.5M | 15.1M | (56.3M) |
| D&A | 20.8M | 12.3M | 9.0M | 4.5M | 6.3M |
| EBIT | 9.9M | 15.2M | 68.5M | 10.6M | (62.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026